To see if your product is a good candidate for the botanical drug IND development:
Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA)
Developed from a Chinese Traditional Medicine (CTM) herb, Dantonic® (T89) is a botanical drug consisting of extracts from 5 herbs including Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng). It also contains borneol and is in a capsule form. It is indicated for angina pectoris.
A Hemp Product-X for Treating Cancer
A hemp product, which is a mixture of cannabis and other botanical products but lacks THC, is now in the early stages of the US FDA IND process. The product is indicated for oncological purposes.
XueZhiKang (XZK) in Patients With Hyperlipidemia
Xue Zhi Kang (XZK) is a formulated traditional chinese medicine (TCM) product. It is an extract from fermented red yeast rice. It passed US FDA phase 1 and phase 2 clinical trials with demonstrated safety and lipid-lowering effects for patients with Hyperlipidemia.
A Hemp Product-Y for Pre-Diabetics and Type II Diabetics
CBD is a non-psychoactive part of the cannabis plant and is believed to have numerous medicinal benefits, including but not limited to; relieving symptoms of seizure disorders, relieving inflammation, anxiety, and nausea. Cannabidivarin (CBDV) is a homologue of CBD, a rare cannabinoid. Research revolving around CBDV is in its beginning stages but gaining momentum. While lesser known than its cousin cannabinoid, CBDV is very promising in its advantageous medicinal effects.
The Product Quality Certification Program
ABDA establish two product certification program:
Premium Quality: an product level overall quality certification
NFC Certification: a test for "Non Foreign Compound" Certification